What are the dosing guidelines, indications, and contraindications for Pseudoeph‑Bromphen‑DM (pseudoephedrine 30 mg, brompheniramine 2 mg, dextromethorphan 10 mg per 5 mL) oral syrup?

Pseudoeph-Bromphen-DM Oral Syrup: Clinical Guidelines

Primary Recommendation

For acute cough associated with the common cold, this combination of first-generation antihistamine (brompheniramine 2 mg), sustained-release decongestant (pseudoephedrine 30 mg), and cough suppressant (dextromethorphan 10 mg) per 5 mL is recommended as effective symptomatic treatment in appropriate patients. 1

Indications

This triple-combination syrup is indicated for:

• Acute cough with post-nasal drip and throat clearing associated with the common cold or upper respiratory tract infections
• Nasal congestion requiring decongestant therapy
• Cough suppression in patients with acute bronchitis or URI

The evidence strongly supports this combination: the ACCP guidelines give a Grade A recommendation (substantial benefit, fair evidence) for first-generation antihistamine/decongestant preparations (specifically brompheniramine with sustained-release pseudoephedrine) in treating acute cough from the common cold 1. Dextromethorphan receives fair evidence support for cough suppression in chronic bronchitis 2.

Dosing Guidelines

Standard adult dosing: 5 mL (one teaspoonful) every 4-6 hours as needed, not to exceed recommended daily limits 3

Pediatric considerations:

• Pseudoephedrine has demonstrated efficacy at 30 mg doses in children aged 6-11 years 4
• However, some European guidelines recommend avoiding pseudoephedrine in patients under age 15 due to cardiovascular and neurological risks 5
• Exercise extreme caution in pediatric populations and consider age-appropriate alternatives

The syrup contains 0.95% alcohol by volume 3.

Absolute Contraindications

Per FDA labeling, do NOT use in 3, 6:

• Newborns and premature infants
• Nursing mothers
• Severe hypertension or severe coronary artery disease
• Patients taking MAO inhibitors (risk of serotonin syndrome with dextromethorphan) 7
• Lower respiratory tract conditions including asthma (antihistamines contraindicated)
• Hypersensitivity to any component

Critical Safety Warnings

Serotonin Syndrome Risk

Dextromethorphan can precipitate serotonin syndrome when combined with SSRIs or other serotonergic agents. A 2025 case report documented serotonin syndrome in a patient on sertraline who took Bromfed DM, presenting with confusion, dilated pupils, myoclonus, and speech difficulty 7. This occurred at therapeutic doses within 3 days of starting the combination.

Action required: Screen all patients for SSRI, SNRI, tricyclic antidepressant, or MAOI use before prescribing. If concurrent serotonergic medication is present, consider alternative cough suppressants or avoid dextromethorphan entirely.

Cardiovascular Risks

Pseudoephedrine causes:

• Increased heart rate (2-4 beats per minute elevation documented) 8
• Vasoconstriction with potential for unpredictable severe cardiovascular events even at low doses 5
• Use with extreme caution in any cardiovascular disease, not just severe disease

Sedation vs. Stimulation

The combination produces paradoxical effects:

• Brompheniramine (first-generation antihistamine) causes sedation
• Pseudoephedrine causes CNS stimulation
• In pediatric studies, somnolence occurred in 71.9% while insomnia occurred in 34.4% 4
• Warn patients about both drowsiness and potential insomnia/nervousness

Clinical Pearls

Duration of treatment: Natural history studies show 25% of patients have persistent cough at day 14 of a common cold 1. However, limit symptomatic treatment to 7 days maximum to avoid complications and medication overuse.

Timing considerations:

• Pseudoephedrine absorption is minimally affected by food (91% bioavailability fed vs. fasted) 9
• Can be taken with or without meals
• Avoid evening doses due to stimulant effects

When NOT to use:

• First week of sinus symptoms: Viral rhinosinusitis is indistinguishable from bacterial sinusitis in the first 7 days; 87% show sinus abnormalities on CT that resolve without antibiotics 1. This combination treats symptoms but does not require bacterial infection diagnosis.
• Newer non-sedating antihistamines are INEFFECTIVE for cough and should not be substituted (Grade D recommendation) 1

Monitoring

• Blood pressure and heart rate in patients with any cardiovascular risk factors
• Mental status changes suggesting serotonin syndrome (confusion, agitation, myoclonus)
• Sedation level affecting daily activities or driving
• Symptom persistence beyond 14 days warrants re-evaluation for post-infectious cough or other etiologies

Alternative Considerations

If contraindications exist:

• Naproxen alone can decrease cough in common cold (Grade A recommendation) 1
• Ipratropium bromide inhaled for cough in URI or bronchitis (Grade A recommendation) 2
• Avoid this combination and use targeted single-agent therapy based on predominant symptom